



BSW Formulary Updates and Recent Decisions – July 2024

New and Updated Shared Care Agreements and Prescribing Guidance

- **New - [Guidance on Prescribing of Low Molecular Weight Heparin \(LMWH\) in adults](#)** – this local guide summarises key safety considerations when using LMWH in primary care. [Dalteparin](#) remains LMWH formulary choice in BSW. The guideline outlines prescribing and monitoring responsibilities across primary/secondary care interface for various indications. Note that while traffic light status is assigned for individual indications, there may be occasions where the usual arrangements for provision are not possible and a pragmatic approach may be required, depending on the situation to ensure that the patient receives supplies of LMWH in a timely manner. Please continue to email bswicb.prescribing@nhs.net for advice if required.
- **New - [Management of Subtherapeutic INRs in Patients on Warfarin](#)** – guidance for managing adults on oral vitamin K antagonists (e.g. warfarin), with an International Normalised Ratio result below their target range.
- **Update – [BSW guidelines for use of melatonin in children](#)** – updated to reflect licence changes in melatonin liquid formulations. On FP10, Ceyesto melatonin 1mg/ml oral solution is a cost-effective choice where a liquid formulation is necessary (liquid is second line if crushed Adaflex tablets are unsuitable) so in primary care, melatonin liquid should be prescribed by brand name Ceyesto. Use of melatonin in paediatrics is assigned a RED traffic light status (TLS) and prescribing is usually retained by community paediatric services for treatment of ADHD. TLS for melatonin in ADULTS depends on indication, read more here [Formulary \(bswformulary.nhs.uk\)](#)
- **Update – [BSW prescribing guidelines for dry eye](#)** - minor update includes the addition of Viscotears HA eye drops (sodium hyaluronate 0.1%) as a preservative-free option for mild-moderate disease and Sodium hyaluronate 0.2% 10ml (Aactive HA PF®).
- **[Dementia drugs](#)** – the formal SCA for Donepezil, Rivastigmine, Galantamine and Memantine for treating Alzheimer’s disease has been retired. When used within their license, these drugs are now assigned as Amber TLS, [*considered suitable for prescribing in primary care following specialist recommendation*]. Further work is required about the use of dementia drugs in off-label indications. For prescribers in Wiltshire, donepezil retains a green TLS as part of the Wiltshire dementia LES, which is currently under discussions as part of wider BSW LES review work.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net